AACR Annual Meeting 2026

Cardiff Oncology's onvansertib shows preclinical promise in reversing HER2-low breast cancer resistance when combined with trastuzumab deruxtecan; data presentation scheduled for April 2026.

Greenwich LifeSciences presents FLAMINGO-01 Phase III trial data at AACR 2026, showing 80% recurrence reduction. Non-HLA-A*02 arm fully enrolled with 250 patients.